Bollu V - Search Results

1

Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients.

Wu EQ, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, Coombs J, Feng W, Cortes J. Wu EQ, et al. Among authors: bollu v. Curr Med Res Opin. 2010 Jan;26(1):61-9. doi: 10.1185/03007990903396469. Curr Med Res Opin. 2010. PMID: 19905880

2

Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.

Rubin JL, Taylor DC, Sanon M, Coombs JH, Bollu VK. Rubin JL, et al. J Manag Care Pharm. 2010 Sep;16(7):482-91. doi: 10.18553/jmcp.2010.16.7.482. J Manag Care Pharm. 2010. PMID: 20726677 Free PMC article.

3

Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.

Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD. Wu EQ, et al. Curr Med Res Opin. 2010 Dec;26(12):2861-9. doi: 10.1185/03007995.2010.533648. Epub 2010 Nov 9. Curr Med Res Opin. 2010. PMID: 21062136

4

Epidemiology, survival, and costs of localized gastrointestinal stromal tumors.

Rubin JL, Sanon M, Taylor DC, Coombs J, Bollu V, Sirulnik L. Rubin JL, et al. Among authors: bollu v. Int J Gen Med. 2011 Feb 14;4:121-30. doi: 10.2147/IJGM.S16090. Int J Gen Med. 2011. PMID: 21475624 Free PMC article.

5

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials.

Signorovitch JE, Wu EQ, Betts KA, Parikh K, Kantor E, Guo A, Bollu VK, Williams D, Wei LJ, DeAngelo DJ. Signorovitch JE, et al. Curr Med Res Opin. 2011 Jun;27(6):1263-71. doi: 10.1185/03007995.2011.576238. Epub 2011 Apr 28. Curr Med Res Opin. 2011. PMID: 21524239 Clinical Trial.

6

Healthcare utilization and costs in patients beginning pharmacotherapy for generalized anxiety disorder: a retrospective cohort study.

Berger A, Edelsberg J, Bollu V, Alvir JM, Dugar A, Joshi AV, Oster G. Berger A, et al. Among authors: bollu v. BMC Psychiatry. 2011 Dec 12;11:193. doi: 10.1186/1471-244X-11-193. BMC Psychiatry. 2011. PMID: 22151689 Free PMC article.

7

The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.

Guérin A, Wu EQ, Bollu VK, Williams D, Guo A, de Leon DP, Quintas-Cardama A. Guérin A, et al. J Med Econ. 2013;16(1):125-33. doi: 10.3111/13696998.2012.693896. Epub 2012 Jun 6. J Med Econ. 2013. PMID: 22587385 Free article.

8

Readmission Risk in Chronic Obstructive Pulmonary Disease Patients: Comparative Study of Nebulized β₂-Agonists.

Bollu V, Guérin A, Gauthier G, Hiscock R, Wu EQ. Bollu V, et al. Drugs Real World Outcomes. 2017 Mar;4(1):33-41. doi: 10.1007/s40801-016-0097-y. Drugs Real World Outcomes. 2017. PMID: 27864792 Free PMC article.

9

Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting β2-agonists.

Chen YJ, Makin C, Bollu VK, Navaie M, Celli BR. Chen YJ, et al. J Med Econ. 2016;19(1):11-20. doi: 10.3111/13696998.2015.1079530. Epub 2015 Sep 11. J Med Econ. 2016. PMID: 26357881 Free article.

10

Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis of hospital data in the United States.

Maziarz RT, Yang H, Liu Q, Wang T, Zhao J, Lim S, Lee S, Dalal A, Bollu V. Maziarz RT, et al. Among authors: bollu v. Leuk Lymphoma. 2022 Sep;63(9):2052-2062. doi: 10.1080/10428194.2022.2060503. Epub 2022 Apr 14. Leuk Lymphoma. 2022. PMID: 35422192 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

34 results

Search Page

Filters